Drug Discovery

Orexin Receptor Agonism: A First-in-Class Approach to Narcolepsy Type 1

The FDA’s approval of ovexorexton marks the first drug targeting the orexin pathway in narcolepsy type 1, addressing the disorder’s full symptom spectrum rather than isolated features.